-急性冠脉综合征的抗栓治疗策略-—培训课件.ppt

* 2005年acc/aha升级了ua/nstemi的指南，强化了在急诊室的治疗，使之更具可操作性 借此总结ua/nstemi的抗栓治疗策略 * 与GUIDELINE相比添加了 2.氯吡格雷应在急诊室近早服用 5.无高危出血因素者术后氯吡格雷服用12个月 * Data are from ISIS-2 and are for patients who were randomly assigned to receive aspirin or placebo for one month. This table should not be used to assess the effects of heparin, because heparin treatment was not randomly assigned. Just before randomly assigning each patient to aspirin or placebo, doctors were asked whether they “planned” to use intravenous heparin for that patient, and on the discharge form they reported whether they had actually done so. Deaths were recorded through the first 35 days, whereas reinfarctions, strokes, and major bleeding episodes were recorded only if they occurred before hospital discharge. Mortality percentages are based on all randomized patients (numbers given at top of columns), whereas percentages for all other events are based only on the 99 percent of patients with discharge forms. Data on heparin use include only patients discharged alive for whom discharge forms were available. IV denotes intravenous. Plus–minus values are SD. The methods used in all tables and figures to analyze the results of individual trials and to combine the results from different trials, with appropriate weight given to each trial, are described in detail elsewhere. ?Of this group, 6 percent were given intravenous heparin, and a further 50 percent were given subcutaneous heparin. ?Of this group, 77 percent were given intravenous heparin, and a further 14 percent were given subcutaneous heparin. * * * *Data are from Collins et al. This table should not be used to assess the effects of aspirin or fibrinolytic therapy, because these treatments were not randomly assigned. Deaths were generally recorded only before hospital discharge, and reinfarctions, strokes, pulmonary embolisms, and major bleeding episodes were recorded only if they occurred before hospital discharge. For the six trials (or trial strata) with routine aspi